IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
IceCure Medical's ProSense breast cancer cryoablation was featured in scientific sessions, posters and workshops at the EUSOBI 2026 Annual Scientific Meeting in Maastricht. Featured 12-month data showed objective response rates of 97.5% in 40 patients treated with cryoablation plus endocrine therapy and 91.7% in 24 patients treated with cryoablation alone.
Key figures
- Drug Name
- ProSense
- Workshop participants
- nearly 70 per workshop
- Patients cryoablation alone
- 24
- Objective response rate cryoablation alone
- 91.7%
- Patients cryoablation plus endocrine therapy
- 40
- Objective response rate cryoablation plus endocrine therapy
- 97.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.